medigraphic.com
ISSN 2007-6053 (Print)
Órgano oficial de difusión de los Hospitales Regionales de Alta Especialidad (HRAE)

2015, Number 4

<< Back Next >>

Evid Med Invest Salud 2015; 8 (4)

Red blood cell concentrate transfusion. Who needs a blood transfusion?

Amador-Medina LF, Escárzaga-Pardavel R

Language: Spanish
References: 26
Page: 180-185
PDF size: 292.77 Kb.


ABSTRACT

There are clinical studies that suggest that a transfusion policy restricted to a hemoglobin concentration of 7 to 8 g/dL should guide the decision to transfuse in most patients. The use of a transfusion threshold with this restriction for hemoglobin level is safe in most patient populations, improves clinical outcomes, and reduces unnecessary transfusion. However, patients should be clinically evaluated when transfusion is considered, even at this level of hemoglobin. Certainly, in most scenarios the transfusion threshold is about 7 g/dL, even though the clinician judgment should determine the indication for transfusion. Physicians should assess the risks and benefits of a blood transfusion.


REFERENCES

  1. Norma Oficial Mexicana NOM-253-SSA1-2012. Para la disposición de sangre humana y sus componentes con fines terapéuticos. Disponible en: http://www.dof.gob.mx/normasOficiales

  2. Guía para el Uso Clínico de la Sangre. 3.a ed. México: Secretaría de Salud; 2007. Disponible en: http://salud.gob.mx/cnts/pdfs/GuiaP

  3. Shander H, Fink A, Javidroozi M, Erhand J, Farmer SL, Corwin H et al. Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. Transfus Med Rev. 2011; 25 (3): 232-246.e53.

  4. Juárez E, Vite M, Marín R, Sánchez S. Auditoría transfusional retrospectiva en el Centro Nacional de la Transfusión Sanguínea. Rev Invest Clin. 2004; 56 (1): 38-42.

  5. Vences M, Gil A, Orozco F, Vega P. Práctica transfusional en pacientes hospitalizados. Rev Med IMSS. 1998; 36 (3): 2011-2015.

  6. Leal SR, Muñoz M, Asuero M, Contreras E, García J, Llau J et al. Documento Sevilla de consenso sobre alternativas a la transfusión de sangre alogénica. Rev Esp Anestesiol Reanim. 2013; 37 (4): 259-283.

  7. Rodríguez MH. Alternativas de la transfusión. Rev Mex Med Tran. 2008; 1: 31-36.

  8. Klein HG, Spahn DR, Carson JL: Red blood cell transfusion in clinical practice. Lancet. 2007; 370: 415-425.

  9. Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah’s Witnesses. Transfusion. 1994; 34: 396-403.

  10. Hebert P, Well G, Blajchman M, Marshall J, Martin C, Pagliarello G et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999; 340: 409-417.

  11. Carson J, Terrin M, Noveck H, Sander D, Chaitman B, Rhoads G et al. Liberal or restrictive transfusion in high risk patients after hip surgery. N Engl J Med. 2011; 365: 2453-2462.

  12. Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013; 358: 11-21.

  13. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013; 39: 165-228.

  14. Holst L, Haase N, Wetterslev J, Wernerman J, Guttormsen A, Karlsson S et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014; 1: 1-11.

  15. Murphy G, Pike K, Rogers C, Wordsworth S, Stokes E, Angelini G et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med. 2015; 372: 997-1008.

  16. Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2012; 157: 49-58.

  17. Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010; 50: 1495-1504.

  18. Rohde JM, Dimcheff DE, Blumberg N, Saint S, Langa KM, Kuhn L et al. Health care-associated infections after red blood cell transfusion: a systematic review and meta-analysis. JAMA. 2014; 311: 1317-1327.

  19. Murphy MF, Wallington TB, Kelsey P, Boulton F, Bruce M, Cohen H et al. Guidelines for the clinical use of red cell transfusion. Br J Haematol. 2001; 113: 24-31.

  20. Klein HG, Anstee DJ. Mollison’s blood transfusion in clinical medicine. 11th ed. Oxford: Wiley-Blackwell; 2006.

  21. Goodnough LT. Risks of blood transfusion. Crit Care Med. 2003; 31 (12 Suppl): S678-S686.

  22. Stack G, Judge JV, Snyder EL. Febrile and non-immune transfusion reactions. In: Rossi EC, Moss GS, Gould SA. Principles of transfusion medicine. 2nd ed. Baltimore, MD: Williams & Wilkins; 1996. p. 773.

  23. AABB Technical Manual. 16th ed. In: Brecher EM. AABB Standards for Blood Banks and Transfusion Services. 25th ed. Bethesda, MD: AABB Press; 2008.

  24. Sandler SG, Eckrich R, Malamut D, Mallory D. Hemagglutination assays for the diagnosis and prevention of IgA anaphylactic transfusion reactions. Blood. 1994; 84: 2031-2035.

  25. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA et al. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev. 2005; 19: 2-10.

  26. Anderson K. Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: Implications for universal irradiation of cellular blood components. Transfusion. 2003; 43: 1652-1654.




2020     |     www.medigraphic.com